Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 865 locations
View Trial Details
Active, not recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • University of Miami Health System Miami, Florida, United States
  • AdventHealth Cancer Institute Orlando, Florida, United States
View all 136 locations
View Trial Details
Active, not recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Active, not recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Norwalk Hospital-oncology Norwalk, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 216 locations
View Trial Details
Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1410 locations
View Trial Details
Active, not recruiting

A Study of Daratumumab

NCT05438043

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Miami Sylvester Cancer Center Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Barnes-jewish Hospital St Louis, Missouri, United States
View all 92 locations
View Trial Details
Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226

Conditions
Bone Marrow Diseases, Chromosome Aberrations, Chronic Disease, +14 more
Locations
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • Florida Cancer Specialists Pan Tallahassee, Florida, United States
  • University of Kentucky Lexington, Kentucky, United States
View all 110 locations
View Trial Details
Active, not recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Cleveland Clinic Florida Weston, Florida, United States
  • Augusta University- Georgia Cancer Center Augusta, Georgia, United States
View all 53 locations
View Trial Details
Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 937 locations
View Trial Details

Related conditions